The use of hormone therapy in most patients with advanced prostate cancerproduces a dramatic positive response followed by a disappointing progression.In many cases, this occurs because treatment is withheld until late in thedisease. Can the grim prognosis of advanced prostate cancer be altered throughthe use of novel agents? Or can outcomes be improved by delivering hormonaltherapy earlier in the disease? The answers are likely yes, as two articlesin this issue of Urology Times suggest (see pages 13 and 24). But the solutionsare not imminent.